The main determinants of HIV-1 coreceptor usage are located in the V3-loop of gp120, although mutations in V2 and gp41 are also known. Incorporation of V2 is known to improve prediction algorithms; however, this has not been confirmed for gp41 mutations.
Methods
Samples with V3 and gp41 genotypes and Trofile assay (Monogram Biosciences, South San Francisco, CA, USA) results were taken from the HOMER cohort (n=444) and from patients screened for the MOTIVATE studies (n=1,916; 859 with maraviroc outcome data). Correlations of mutations with tropism were assessed using Fisher's exact test and prediction models trained using support vector machines. Models were validated by cross-validation, by testing models from one dataset on the other, and by analysing virological outcome.
Results
Several mutations within gp41 were highly significant for CXCR4 usage; most strikingly an insertion occurring in 7.7% of HOMER-R5 and 46.3% of HOM-ER-X4 samples (MOTIVATE 5.7% and 25.2%, respectively). Models trained on gp41 sequence alone achieved relatively high areas under the receiver- operating characteristic curve (AUCs; HOMER 0.713 and MOTIVATE 0.736) that were almost as good as V3 models (0.773 and 0.884, respectively). However, combining the two regions improved predictions only marginally (0.813 and 0.902, respectively). Similar results were found when models were trained on HOMER and validated on MOTIVATE or vice versa. The difference in median log viral load decrease at week 24 between patients with R5 and X4 virus was 1.65 (HOMER 2.45 and MOTIVATE 0.79) for V3 models, 1.59 for gp41-models (2.42 and 0.83, respectively) and 1.58 for the combined predictor (2.44 and 0.86, respectively).
Conclusions
Several mutations within gp41 showed strong correlation with tropism in two independent datasets. However, incorporating gp41 mutations into prediction models is not mandatory because they do not improve substantially on models trained on V3 sequences alone.
References
1.
AlkhatibG., CombadiereC., BroderC.C.CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science1996; 272: 1955–1958.
2.
BergerE.A., DomsR.W., FenyoE.M.A new classification for HIV-1. Nature1998; 391: 240.
3.
BergerE.A., MurphyP.M., FarberJ.M.Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. Annu Rev Immunol1999; 17: 657–700.
4.
ClaphamP.R., McKnightA.Cell surface receptors, virus entry and tropism of primate lentiviruses. J Gen Virol2002; 83: 1809–1829.
5.
DengH., LiuR., EllmeierW.Identification of a major co-receptor for primary isolates of HIV-1. Nature1996; 381: 661–666.
6.
DragicT., LitwinV., AllawayG.P.HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature1996; 381: 667–673.
7.
FengY., BroderC.C., KennedyP.E., BergerE.A.HIV-1 entry cofactor: functional cDNA cloning of a seventransmembrane, G protein-coupled receptor. Science1996; 272: 872–877.
8.
MooreJ.P., KitchenS.G., PugachP., ZackJ.A.The CCR5 and CXCR4 coreceptors – central to understanding the transmission and pathogenesis of human immunodeficiency virus type 1 infection. AIDS Res Hum Retroviruses2004; 20: 111–126.
9.
ZhangL., HeT., HuangY.Chemokine coreceptor usage by diverse primary isolates of human immunodeficiency virus type 1. J Virol1998; 72: 9307–9312.
10.
BrummeZ.L., GoodrichJ., MayerH.B.Molecular and clinical epidemiology of CXCR4-using HIV-1 in a large population of antiretroviral-naive individuals. J Infect Dis2005; 192: 466–474.
11.
KupferB., KaiserR., RockstrohJ.K., MatzB., SchneweisK.E.Role of HIV-1 phenotype in viral pathogenesis and its relation to viral load and CD4+ T-cell count. J Med Virol1998; 56: 259–263.
12.
MoyleG.J., WildfireA., MandaliaS.Epidemiology and predictive factors for chemokine receptor use in HIV-1 infection. J Infect Dis2005; 191: 866–872.
13.
DaarE.S., KeslerK.L., PetropoulosC.J.Baseline HIV type 1 coreceptor tropism predicts disease progression. Clin Infect Dis2007; 45: 643–649.
14.
DorrP., WestbyM., DobbsS.Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob Agents Chemother2005; 49: 4721–4732.
15.
WestbyM., van der RystE.CCR5 antagonists: host-targeted antivirals for the treatment of HIV infection. Antivir Chem Chemother2005; 16: 339–354.
16.
SuleimanJ., ZingmanB.S., DiazR.S.Vicriviroc in combination therapy with an optimized regimen for treatment-experienced subjects: 48-week results of the VICTOR-E1 phase 2 trial. J Infect Dis2010; 201: 590–599.
17.
WhitcombJ.M., HuangW., FransenS.Development and characterization of a novel single-cycle recombinant-virus assay to determine human immunodeficiency virus type 1 coreceptor tropism. Antimicrob Agents Chemother2007; 51: 566–575.
18.
BraunP., WiesmannF.Phenotypic assays for the determination of coreceptor tropism in HIV-1 infected individuals. Eur J Med Res2007; 12: 463–472.
19.
TrouplinV., SalvatoriF., CappelloF.Determination of coreceptor usage of human immunodeficiency virus type 1 from patient plasma samples by using a recombinant phenotypic assay. J Virol2001; 75: 251–259.
20.
LengauerT., SanderO., SierraS., ThielenA., KaiserR.Bioinformatics prediction of HIV coreceptor usage. Nat Biotechnol2007; 25: 1407–1410.
SingT., LowA.J., BeerenwinkelN.Predicting HIV coreceptor usage on the basis of genetic and clinical covariates. Antivir Ther2007; 12: 1097–1106.
23.
LowA.J., DongW., ChanD.Current V3 genotyping algorithms are inadequate for predicting X4 co-receptor usage in clinical isolates. AIDS2007; 21: F17–F24.
24.
HarriganP., McGovernR., DongW.Screening for HIV tropism using population-based V3 genotypic analysis: a retrospective virological outcome analysis using stored plasma screening samples from MOTIVATE-1.5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention. 19–22 July 2009, Cape Town, South Africa. Abstract WELBA101.
25.
De JongJ.J., DerondeA., KeulenW., TersmetteM., GoudsmitJ.Minimal requirements for the human-immunodeficiency-virus type-1 V3 domain to support the syncytium-inducing phenotype: analysis by single aminoacid substitution. J Virol1992; 66: 6777–6780.
26.
FouchierR.A.M., BrouwerM., BroersenS.M., SchuitemakerH.Simple determination of human-immunodeficiency-virus type-1 syncytium-inducing V3 Genotype by PCR. J Clin Microbiol1995; 33: 906–911.
27.
FouchierR.A.M., GroeninkM., KootstraN.A.Phenotype-associated sequence variation in the 3rd variable domain of the human-immunodeficiency-virus type-1 Gp120 molecule. J Virol1992; 66: 3183–3187.
28.
KuikenC.L., DejongJ.J., BaanE., KeulenW., TersmetteM., GoudsmitJ.Evolution of the V3 envelope domain in proviral sequences and isolates of human-immunodeficiency-virus type-1 during transition of the viral biological phenotype. J Virol1992; 66: 4622–4627.
29.
BoydM.T., SimpsonG.R., CannA.J., JohnsonM.A., WeissR.A.A single amino-acid substitution in the V1 loop of human-immunodeficiency-virus type-1 Gp120 alters cellular tropism. J Virol1993; 67: 3649–3652.
30.
HoffmanN.G., Seillier-MoiseiwitschF., AhnJ., WalkerJ.M., SwanstromR.Variability in the human immunodeficiency virus type 1 gp120 Env protein linked to phenotype-associated changes in the V3 loop. J Virol2002; 76: 3852–3864.
31.
KoitoA., StamatatosL., Cheng-MayerC.Small amino acid sequence changes within the V2 domain can affect the function of a T-cell line-tropic human immunodeficiency virus type 1 envelope gp120. Virology1995; 206: 878–884.
FouchierR.A., BroersenS.M., BrouwerM.Temporal relationship between elongation of the HIV type 1 glycoprotein 120 V2 domain and the conversion toward a syncytium-inducing phenotype. AIDS Res Hum Retroviruses1995; 11: 1473–1478.
GroeninkM., FouchierR.A., BroersenS.Relation of phenotype evolution of HIV-1 to envelope V2 configuration. Science1993; 260: 1513–1516.
36.
HuangW., TomaJ., FransenS.Coreceptor tropism can be influenced by amino acid substitutions in the gp41 transmembrane subunit of human immunodeficiency virus type 1 envelope protein. J Virol2008; 82: 5584–5593.
37.
ProsperiM.C., FantiI., UliviG., MicarelliA., De LucaA., ZazziM.Robust supervised and unsupervised statistical learning for HIV type 1 coreceptor usage analysis. AIDS Res Hum Retroviruses2009; 25: 305–314.
38.
HoggR.S., YipB., ChanK.J.Rates of disease progression by baseline CD4 cell count and viral load after initiating triple-drug therapy. JAMA2001; 286: 2568–2577.
39.
GulickR.M., LalezariJ., GoodrichJ.Maraviroc for previously treated patients with R5 HIV-1 infection. N Engl J Med2008; 359: 1429–1441.
40.
FätkenheuerG., NelsonM., LazzarinA.Subgroup analyses of maraviroc in previously treated R5 HIV-1 infection. N Engl J Med2008; 359: 1442–1455.
41.
R Development Core Team (Editors).R: A language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing2005.
42.
SingT., SanderO., BeerenwinkelN., LengauerT.ROCR: visualizing classifier performance in R. Bioinformatics2005; 21: 3940–3941.
43.
SingT., SvicherV., BeerenwinkelN.Characterization of novel HIV drug resistance mutations using clustering, multidimensional scaling and SVM-based feature ranking.9th European Conference on Principles and Practice of Knowledge Discovery in Databases. 3–7 October 2005, Porto, Portugal. Abstract 96.
44.
ThompsonJ.D., HigginsD.G., GibsonT.J.CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. Nucleic Acids Res1994; 22: 4673–4680.
45.
CristianiniN., Shawe-TaylorJ.An introduction to support vector machines: and other kernel-based learning methods. Cambridge: Cambridge University Press2000.
